Precirix presents preclinical data of its FAP-targeting compound at the SNMMI annual meeting
Brussels, Belgium, 10 June 2022 – Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, will present preclinical data of its FAP-targeting single domain antibody (sdAb) linked to multiple isotopes at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 annual meeting, 11-14 June in Vancouver, BC.
Precirix generated a sdAb with picomolar affinity for FAP (CAM-FAP), a target of strong interest in the radiopharmaceutical field due to its high expression on tumor-associated fibroblasts of epithelial derived cancers and limited expression in healthy adult tissue. At the SNMMI conference, Precirix will present the assessment of therapeutic efficacy of CAM-FAP after radiolabeling with the beta particle emitter Iodine-131 and the alpha particle emitter Actinium-225. Both CAM-FAP-I-131 and CAM-FAP-Ac-225 demonstrate high and sustained tumor targeting in vivo, translating into dose-dependent therapeutic efficacy in FAP-expressing tumor xenografted mice. The study confirms the potential of radiolabeled CAM-FAP for targeted radiotherapy in FAP-expressing cancers and warrants its clinical translation.
CAM-H2, Precirix’ lead compound, is currently in Phase I/II clinical development for the treatment of HER2- positive metastatic cancer. CAM-FAP will be the company’s second product candidate to enter clinical phase. Precirix plans to submit an IND by YE2022 and to initiate clinical trials in 2023.
2457 – Preclinical endoradiotherapy using a radiolabeled single-domain antibody targeting Fibroblast Activation Protein (June 14, 4pm PDT)
Precirix is a private, clinical-stage biopharmaceutical company founded in 2014 as a spin-off from the VUB, dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies labeled with radioisotopes. The company has a broad pipeline with one product candidate in a Phase I/II clinical trial and two in advanced preclinical stage. Research on multiple isotopes, linker technology and combination therapies further expand the platform. Precirix’ technology also allows for a theranostic approach, where patients can be selected using a low dose/imaging version of the product, followed by a therapeutic dose for treatment. Precirix received grant funding from Innoviris Brussels to support this research.